A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor

Cancer Research

Volumn 72, Issue 7, 2012, Pages 1844-1852

  Urbanska, Katarzyna ^a   Lanitis, Evripidis ^a   Poussin, Mathilde ^a   Lynn, Rachel C ^a   Gavin, Brian P ^a   Kelderman, Sander ^a   Yu, Jason ^a   Scholler, Nathalie ^a   Powell, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVIDIN; BIOTIN; CD4 ANTIGEN; CD8 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; EPITHELIAL CELL ADHESION MOLECULE MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; LENTIVIRUS VECTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; BINDING KINETICS; BIOTINYLATION; CANCER CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL SPECIFICITY; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; GENETIC ENGINEERING; HUMAN; HUMAN CELL; LYMPHOCYTE SUBPOPULATION; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR VOLUME;

EID: 84859383718     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3890     Document Type: Article

References (19)

1. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993;90:720-4. (Pubitemid 23028937)
2. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010;116:4099-102.
3. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-33.
4. Kohn DB, Dotti G, Brentjens R, Savoldo B, Jensen M, Cooper LJ, et al. CARs on track in the clinic. Mol Ther 2011;19:432-8.
5. Song DG, Ye Q, Carpenito C, Poussin M, Wang LP, Ji C, et al. In Vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res 2011;71:4617-27.
6. Perez EE, Riley JL, Carroll RG, von Laer D, June CH. Suppression of HIV-1 infection in primary CD4 T cells transduced with a self-inactivating lentiviral vector encoding a membrane expressed gp41-derived fusion inhibitor. Clin Immunol 2005;115:26-32. (Pubitemid 40616165)
7. Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N, et al. Redirected antitumor activity of primary human lymphocytes transduced with a fully Human anti-mesothelin chimeric receptor. Mol Ther 2011 Nov 29 [Epub ahead of print].
8. Green NM, Toms EJ. The properties of subunits of avidin coupled to sepharose. Biochem J 1973;133:687-700.
9. Laitinen OH, Marttila AT, Airenne KJ, Kulik T, Livnah O, Bayer EA, et al. Biotin induces tetramerization of a recombinant monomeric avidin. A model for protein-protein interactions. J Biol Chem 2001;276:8219-24.
10. Scholler N, Garvik B, Quarles T, Jiang S, Urban N. Method for generation of in vivo biotinylated recombinant antibodies by yeast mating. J Immunol Methods 2006;317:132-43. (Pubitemid 44816326)
11. Bergan L, Gross JA, Nevin B, Urban N, Scholler N. Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin- dependent cell attachment. Cancer Lett 2007;255: 263-74. (Pubitemid 47268642)
12. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001;19:225-52. (Pubitemid 32368035)
13. Koehler H, Kofler D, Hombach A, Abken H. CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an antitumor cell attack. Cancer Res 2007;67:2265-73. (Pubitemid 46424246)
14. Stratton SL, Horvath TD, Bogusiewicz A, Matthews NI, Henrich CL, Spencer HJ, et al. Plasma concentration of 3-hydroxyisovaleryl carnitine is an early and sensitive indicator of marginal biotin deficiency in humans. Am J Clin Nutr 2010;92:1399-405.
15. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006;12: 6106-15. (Pubitemid 44703776)
16. Lamers CH, Willemsen R, van Elzakker P, van Steenbergen-Langeveld S, Broertjes M, Oosterwijk-Wakka J, et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 2011;117:72-82.
17. Johnson LA, Heemskerk B, Powell DJ Jr, Cohen CJ, Morgan RA, Dudley ME, et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol 2006;177:6548-59. (Pubitemid 44628874)
18. Samuel A, Paganelli G, Chiesa R, Sudati F, Calvitto M, Melissano G, et al. Detection of prosthetic vascular graft infection using avidin/indium-111- biotin scintigraphy. J Nucl Med 1996;37:55-61.
19. Paganelli G, Magnani P, Zito F, Villa E, Sudati F, Lopalco L, et al. Threestep monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 1991;51:5960-6.